Please use this identifier to cite or link to this item:
Title: Emerging therapies for the treatment of skeletal muscle wasting in chronic obstructive pulmonary disease
Authors: Passey, Samantha L;Hansen, Michelle J;Bozinovski, Steven;McDonald, Christine F;Holland, Anne E;Vlahos, Ross
Issue Date: Oct-2016
EDate: 2016-06-29
Citation: Pharmacology & Therapeutics 2016; 166: 56-70
Abstract: Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that constitutes a major global health burden. A significant proportion of patients experience skeletal muscle wasting and loss of strength as a comorbidity of their COPD, a condition that severely impacts on their quality of life and survival. At present, the lung pathology is considered to be largely irreversible; however, the inherent adaptability of muscle tissue offers therapeutic opportunities to tackle muscle wasting and potentially reverse or delay the progression of this aspect of the disease, to improve patients' quality of life. Muscle wasting in COPD is complex, with contributions from a number of factors including inflammatory cytokines, oxidative stress, growth and anabolic hormones, nutritional status, and physical activity. In this review, we discuss current and emerging therapeutic approaches to treat muscle wasting in COPD, including a number of pharmacological therapies that are in development for muscle atrophy in other pathological states that could be of relevance for treating muscle wasting in COPD patients.
DOI: 10.1016/j.pharmthera.2016.06.013
PubMed URL:
Type: Journal Article
Subjects: Chronic obstructive pulmonary disease (COPD)
Pulmonary rehabilitation
Skeletal muscle
Therapeutic strategies
Appears in Collections:Journal articles

Files in This Item:
File Description SizeFormat 
1-s2.0-S0163725816301036-main.pdf907.59 kBAdobe PDFThumbnail

Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.